Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 14/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 5/20 | 0.37 |
| ▸ | HTR1A | P08908 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | HTR7 | P34969 | 4/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287045 | 0.90 | CACNA1B (0.65) | CACNA1BCACNA1CNR1I2CYP3A4 | |
| SCHEMBL4284794 | 0.76 | CACNA1B (0.46) | CACNA1BHTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4290517 | 0.74 | CACNA1B (0.60) | CACNA1BCACNA1CHTR2AHTR1ADRD2 | |
| SCHEMBL14997384 | 0.73 | HTR2A (0.61) | CACNA1BHTR2ADRD2 | |
| SCHEMBL4285152 | 0.72 | SIGMAR1 (0.56) | CACNA1BHTR2A | |
| SCHEMBL13880078 | 0.71 | HTR2A (0.51) | CACNA1BHTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4282387 | 0.71 | ALDH1A1 (0.51) | CACNA1BHTR2ADRD2HTR2C | |
| SCHEMBL4283391 | 0.70 | CACNA1B (0.56) | CACNA1BHTR7 | |
| SCHEMBL4286138 | 0.70 | MEN1 (0.50) | CACNA1BHTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4285276 | 0.69 | CHRM4 (0.56) | CACNA1BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1814851-B1 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2013-06-05 | — | — | EP | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | CACNA1B 3/4885CACNA1C 5/4885HTR2A 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.